Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment

被引:40
作者
Hooijberg, JH
de Vries, NA
Kaspers, GJL
Pieters, R
Jansen, G
Peters, GJ
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol, NL-1007 MB Amsterdam, Netherlands
[3] Sophia Childrens Univ Hosp, Dept Pediat Oncol, Rotterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Rheumatol, NL-1007 MB Amsterdam, Netherlands
关键词
folates; folate homeostasis; multiple drug resistance; multidrug resistance proteins; breast cancer resistance protein; antifolates; ABC transporters;
D O I
10.1007/s00280-005-0141-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Over the past decades, numerous reports have covered the crucial role of multidrug resistance (MDR) transporters in the efficacy of various chemotherapeutic drugs. Specific cell membrane-associated transporters mediate drug resistance by effluxing a wide spectrum of toxic agents. Although several excellent reviews have addressed general aspects of drug resistance, this current review aims to highlight implications for the efficacy of folate-based and other types of chemotherapeutic drugs. Folates are vitamins that are daily required for many biosynthetic processes. Folate supplementation in our diet may convey protective effects against several diseases, including cancers, but folate supplementation also makes up an essential part of several current cancer chemotherapeutic regimens. Traditionally, the folate leucovorin, for instance, is used to reduce antifolate toxicity in leukemia or to enhance the effect of the fluoropyrimidine 5-fluorouracil in some solid tumors. More recently, it has also been noted that folic acid has the ability to increase antitumor activity of several structurally unrelated regimens, such as alimta/pemetrexed and cisplatin. Moreover, studies from our laboratory demonstrated that folates could modulate the expression and activity of at least two members of the MDR transporters: MRP1/ABCC1, and the breast cancer resistance protein BCRP/ABCG2. Thus, folate supplementation may have differential effects on chemotherapy: (1) reduction of toxicity, (2) increase of antitumor activity, and (3) induction of MRP1 and BCRP associated cellular drug resistance. In this review the role of MDR proteins is discussed in further detail for each of these three items from the perspective to optimally exploit folate supplementation for enhanced chemotherapeutic efficacy of both antifolate-based chemotherapy and other classes of chemotherapeutic drugs.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 152 条
[1]  
Alati T, 1996, CANCER RES, V56, P2331
[2]  
Allen JD, 2002, CANCER RES, V62, P2294
[3]   Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells [J].
Assaraf, YG ;
Rothem, L ;
Hooijberg, JH ;
Stark, M ;
Ifergan, I ;
Kathmann, I ;
Dijkmans, BAC ;
Peters, GJ ;
Jansen, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) :6680-6686
[4]   Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells [J].
Assaraf, YG ;
Goldman, ID .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (28) :17460-17466
[5]   The role of half-transporters in multidrug resistance [J].
Bates, SE ;
Robey, R ;
Miyake, K ;
Rao, K ;
Ross, DD ;
Litman, T .
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2001, 33 (06) :503-511
[6]  
Belinsky MG, 2002, CANCER RES, V62, P6172
[7]  
Berger W, 1997, INT J CANCER, V73, P84
[8]  
BERTINO JR, 1977, SEMIN ONCOL, V4, P203
[9]   ODE TO METHOTREXATE [J].
BERTINO, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :5-14
[10]   The role of multidrug, transporters in drug availability, metabolism and toxicity [J].
Bodó, A ;
Bakos, E ;
Szeri, F ;
Váradi, A ;
Sarkadi, B .
TOXICOLOGY LETTERS, 2003, 140 :133-143